pipette
ESEspañol

The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial

Anna Maria Di Giacomo, Matteo Simonelli, Agnese Losurdo, Pavlina Spiliopoulou, Vincenzo D’Alonzo, G. Amato, Monica Valente, Hugo Barcenilla, Anette Johnsson, Laura González, Ziyang Tan, Tadepally Lakshmikanth, Petter Brodin, Michael Lahn, Giusy Di Conza, Rebeca Zorrilla, Lars Anders van der Veen, Alessio Bevilacqua, Paramjit Kaur, Tracey Hammett, Marco Durini, Andrea Corsi, Nikhil Sindhwani, Mariaelena Occhipinti, Robert Snijder, Ayad Abdul-Ahad, Anikó Meijer, Umberto Postiglione, Gregory Price, Gillian Hopton, Emily Wood, Vincent Vuaroqueaux, Anne-Lise Peille, Jill Graham, Ming Jye Poi, David B. Spetzler, Carmelo Carlo‐Stella, Armando Santoro, Thomas R. Jeffry Evans, Michele Maio

Peer-reviewed journalReal-world use

In the authors' words

Phosphatidylinositol 3-kinase delta (PI3Kδ) promotes tumour cell growth directly or indirectly by activating immune-suppressive cells. In contrast to previous PI3Kδ inhibitors, roginolisib is a selective, non-ATP competitive inhibitor, which locks PI3Kδ into an inactive state and causes an allosteric modulation. In a First-in-Human dose study, continuous daily dosing of roginolisib was investigated in patients with solid and haematologic malignancies. In Part A, 24 patients received escalating doses of roginolisib. In Part B, 20 mostly pre-treated metastatic uveal melanoma (mUM) patients received a dose associated with continuous PI3Kδ inhibition of >90%. The primary endpoint was safety, and secondary endpoints included pharmacokinetic (PK) and pharmacodynamic (PD) profile, clinical anti-tumour responses assessments. Exploratory endpoints included immunophenotyping, proteomics, genomics. No Dose Limiting Toxicity or drug related toxicities requiring dose modifications were observed ( ≥ Grade 3 toxicities: 3/44; 6.8%). In mUM, median Overall Survival (mOS) was 20.8 months (data-cut off December 2023) and 18.4 months (data-cut-off February 2026). mOS in mUM patients with Stable Disease at Week 16 ( = Cycle 5) was 28.5 months, while patients who progressed at Week 16 had a median OS of 12.3 months. Roginolisib was safe, had a predictable PK profile, T regulatory cell abundance was decreased while activated CD8+ T cells increased together with soluble plasma IL-15. ClinicalTrials.gov registration: NCT04328844. First generation inhibitors of phosphatidylinositol 3-kinase delta (PI3Kδ) had limited selectivity due to the conserved ATP binding pocket, resulting in toxicity when used as anti-cancer agent. Here, the authors report the results of a first-in-human clinical trial of Roginolisib, a next generation conformation-selective PI3Kδ inhibitor, in patients with advanced or metastatic cancer with dose expansion in patients with metastatic uveal melanoma.

Main resultThe abstract does not state a limitation.

In plain words AI summary

Roginolisib is a new cancer drug that locks PI3Kδ, a protein that helps tumors grow, into an inactive shape. In a first-in-human trial, 44 patients with advanced cancers received daily roginolisib, including 20 with metastatic uveal melanoma. The drug was safe, with only 6.8% of patients having serious side effects and no dose reductions needed. Patients with metastatic uveal melanoma lived a median of 20.8 months, and those with stable disease at 16 weeks lived 28.5 months. The drug decreased immune-suppressing cells and increased cancer-fighting cells in patients.

Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.

Appeared: Sunday, October 11. Nature Communications. Peer-reviewed journal.

DOI: 10.1038/s41467-026-77358-7